Trial Profile
A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Hyperammonaemia
- Focus Adverse reactions; Registrational
- Sponsors Hyperion Therapeutics
- 30 Nov 2015 According to Horizon Pharma media release, the European Commission has approved glycerol phenylbutyrate oral liquid (RAVICTI) for treatment of urea cycle disorders in patients two months of age and older.
- 26 Jun 2014 New trial record